Thursday, May 26, 2016| Latest E-book
You are here:
Novartis
#

Novartis

Articles

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%

Dec 31, 2015

Warning letters for pharma cos galore: Now Cadila Healthcare faces USFDA heat, stock tanks 16%

The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility #Sun Pharmaceuticals #Cadila Healthcare #US FDA #Novartis #Dr Reddy's Lab #Halol plant
India needs predictable IPR regime, says Novartis

Nov 17, 2015

India needs predictable IPR regime, says Novartis

If the whole data regulatory process becomes predictable in the long run, it makes investment in the country more sustainable, said Novartis Pharma AG, Global Head of Development, Established Medicines Franchise, Lutz Hegemann. #Health #CompanyWatch #World Trade Organization #Novartis #Pharma industry #IPR regime #Compulsory License #Lutz Hegemann
Natco Pharma gains 4.5% after filing ANDA with USFDA

Feb 10, 2015

Natco Pharma gains 4.5% after filing ANDA with USFDA

Natco Pharma has filed new product applications with the US health regulator for generic version of drugs used in the treatment of nervous system disease and cancer. #India #US #Generic drug #generic drug makers #Sanofi #Natco Pharma #Novartis #Jevtana #ANDA #Cabazitaxel #Fingolimod #Gilenya
Delhi HC bars Cipla from selling cheaper copy of Novartis respiratory drug

Jan 14, 2015

Delhi HC bars Cipla from selling cheaper copy of Novartis respiratory drug

Cipla, India's fourth-largest generic drugmaker by revenue, had launched its copy of Onbrez in New Delhi in October last year at a fifth of the original drug's price, citing urgent unmet need in India. #India #NewsTracker #Delhi High Court #Cipla #Novartis #respiratory drug #Onbrez
Novartis sues Cipla for infringing respiratory drug patent

Dec 17, 2014

Novartis sues Cipla for infringing respiratory drug patent

Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. #Cipla #Lupin #Patent #Pharma #US FDA #Novartis #sue #USTR #generic #Onbrez
Did Tata Memorial Hospital intentionally loot its cancer patients?

Nov 23, 2014

Did Tata Memorial Hospital intentionally loot its cancer patients?

Tata Memorial Hospital in Mumbai has admitted to overcharging cancer patients for a Novartis-branded oncology medicine over the last nine months, #Novartis #Tata Memorial Hospital #cancer patients #oncology medicine
Beyond tablets: World's biggest drugmaker Novartis taking a closer look at tech

Nov 18, 2014

Beyond tablets: World's biggest drugmaker Novartis taking a closer look at tech

The Swiss group has already taken tentative steps, signing a deal with Google Inc in July to develop contact lenses to help diabetics track blood glucose levels #Google #Technology #Apple #Drugs #Novartis
DIPP looks into Cipla's demand that Novartis's patent for respiratory drug be revoked

Nov 02, 2014

DIPP looks into Cipla's demand that Novartis's patent for respiratory drug be revoked

The Department of Industrial Policy and Promotion (DIPP) has started the exercise on Cipla's demand. #India #Cipla #DIPP #Novartis #respiratory drug
Ouch: NPPA slaps Novartis with Rs 300 cr fine for over pricing

Oct 13, 2014

Ouch: NPPA slaps Novartis with Rs 300 cr fine for over pricing

The NPPA had put diclofenac, a key ingredient of Novartis's Voveran, under direct price control in May 2013. #India #drug #Novartis #painkiller #NPPA #diclofenac